

Null Results in Brief

One-Carbon Metabolism and Breast Cancer Risk: No Association of *MTHFR*, *MTR*, and *TYMS* Polymorphisms in the GENICA Study from Germany

Christina Justenhoven,¹ Ute Hamann,² Christiane B. Pierl,³ Sylvia Rabstein,³ Beate Pesch,³ Volker Harth,³ Christian Baisch,^{1,2} Caren Vollmert,⁴ Thomas Illig,⁴ Thomas Brüning,³ Yon Ko,⁵ and Hiltrud Brauch¹

¹Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany; ²Deutsches Krebsforschungszentrum Heidelberg, Heidelberg, Germany; ³Berufsgenossenschaftliches Forschungsinstitut für Arbeitsmedizin, Ruhr University Bochum, Bochum, Germany; ⁴GSF-National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg, Germany; and ⁵Department of Internal Medicine, Johanniter-Krankenhaus and University of Bonn, Bonn, Germany

Introduction

Neoplastic development and growth are suspected to be influenced by availability and metabolism of folate due to effects on gene expression through DNA methylation and on genome integrity through DNA synthesis and repair (1-3). Key enzymatic regulators are methylene-tetrahydrofolate reductase (*MTHFR*) reducing 5,10-methylene-tetrahydrofolate to 5-methyl-tetrahydrofolate, the plasma form of folate and carbon donor for the remethylation of homocysteine to methionine (4), the methionine synthase (*MTR*) catalyzing methylation towards *S*-adenosyl-methionine (4), and thymidylate synthase (*TYMS*) catalyzing both the conversion of 5,10-methylene-tetrahydrofolate to dihydrofolate and of deoxyuridylate to deoxythymidylate, a rate-limiting nucleotide of DNA synthesis (5). Common variants *MTHFR*_677_C>T Ala²²²Val and *MTHFR*_1298_A>C Glu⁴²⁹Ala are associated with reduced *in vitro* enzyme activity (6-8), thereby increasing the availability of folate for thymidylate and purine synthesis, affect mRNA level in case of the *TYMS*_1494_del (TAAAGT) polymorphism (9), or are thought to affect the enzymatic activity and induce modest homocysteine reduction and DNA hypomethylation in case of the *MTR*_2756_A>G Asp⁹¹⁹Gly polymorphism (10-12). Although *MTHFR* variants are associated with a decreased risk for colon cancer (13), conflicting data on their association with breast cancer exist (14-25). For this reason, we investigated *MTHFR*, *MTR*, and *TYMS* polymorphisms in a population-based breast cancer case-control study (GENICA) from Germany for their potential role in breast cancer risk.

Materials and Methods

Study Population. The GENICA breast cancer case-control study, including 688 incident cases and 724 age-matched,

population-based controls from the Greater Bonn Region, Germany, has been described previously (26, 27). In brief, breast cancer cases were included based on a histopathologic diagnosis of primary breast cancer. Cases and controls were eligible if they were of Caucasian ethnicity, currently residing in the study region, and were below age 80 years. The GENICA study was approved by the Ethic's Committee of the University of Bonn. All study participants gave written informed consent.

***MTHFR*, *MTR*, and *TYMS* Genotyping.** Genomic DNA was isolated from heparinized blood samples (Puregene, Gentra Systems, Inc., Minneapolis, MN) and subjected to genotyping by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the Sequenom system (Sequenom, San Diego, CA) as previously described (26, 28). We analyzed the single nucleotide polymorphisms *MTHFR*_677_C>T (rs1801133), *MTHFR*_1298_A>C (rs1801131), and *MTR*_2756_A>G (rs1805087) as well as the biallelic *TYMS*_1494_del (TAAAGT) polymorphism (5).

Statistical Methods. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using SAS/STAT software, version 8.02 (29). Risk estimates for the development of breast cancer were calculated as OR with 95% CI using logistic regression analysis, conditional on age (<45, 45 to <50, 50 to <55, 55 to <60, 60 to <65, 65 to <70, ≥70 years). Potential risks were adjusted (OR_{adj}) for known risk factors, such as menopausal status (premenopausal and postmenopausal), body mass index (<20, ≥20 to <25, ≥25 to 30, ≥30), smoking status (never, former, current), history of breast cancer in mother and sisters (no/yes), parity (0 and ≥1), use of hormone replacement therapy (none, >0 to <10, ≥10 years), and use of oral contraceptives (none, >0 to <10, ≥10 years). Data were stratified for menopausal status, body mass index, smoking status, history of breast cancer in mother and sisters, parity, hormone replacement therapy, oral contraceptives, and age at first child birth (nulliparous, <20, ≥20-30, ≥30 years). Multiple testing was accounted for by Bonferroni correction. PHASE was used for the estimation of *MTHFR* haplotypes (30, 31).

Results

We obtained genotyping data at *MTHFR*_677_C>T, *MTHFR*_1298_A>C, *MTR*_2756_A>G, and *TYMS*_1494_del (TAAAGT) at a mean call rate of 96%. All genotype frequencies were in Hardy-Weinberg equilibrium. No statistically significant differences were observed between cases and

Cancer Epidemiol Biomarkers Prev 2005;14(12):3015-8

Received 8/2/05; revised 8/11/05; accepted 9/29/05.

Grant support: Federal Ministry of Education and Research Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0, and 01KW0114; Robert Bosch Foundation of Medical Research, Stuttgart, Germany; Deutsches Krebsforschungszentrum, Heidelberg, Germany; Berufsgenossenschaftliches Forschungsinstitut für Arbeitsmedizin Bochum, Germany; and Medizinische Universitäts-Poliklinik, Bonn, Germany.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Hiltrud Brauch, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, D 70376 Stuttgart, Germany. Phone: 49-711-8101-3705; Fax: 49-711-859-295. E-mail: hiltrud.brauch@ikp-stuttgart.de

Copyright © 2005 American Association for Cancer Research.

doi:10.1158/1055-9965.EPI-05-0592

controls. This was true for all cases and controls as well as cases and controls stratified for menopausal status (Table 1). Upon stratification of *MTHFR*_677_C>T data for smoking, history of breast cancer in mother or sister, and hormone replacement therapy use, we observed significant associations that vanished following Bonferroni correction (data not shown). This was also the case for stratifications of *MTHFR*_1298_A>C data for parity and hormone replacement therapy use, of *MTR*_2756_A>G data for body mass index and smoking, and of *TYMS*_1494_del (TAAAGT) data for body mass index (data not shown).

None of the possible genotype combinations of *MTHFR*_677_C>T, *MTHFR*_1298_A>C, *MTR*_2756_A>G, and *TYMS*_1494_del (TAAAGT) showed differences between cases and

controls. When phase was established for *MTHFR* polymorphisms, we observed haplotype frequencies that differed from the expected frequencies (Table 2). A borderline significant association of *MTHFR*_677_C/*MTHFR*_1298_C and *MTHFR*_677_T/*MTHFR*_1298_A with breast cancer risk was observed (Table 2) that vanished following Bonferroni correction.

Discussion

Previous conflicting reports on an association of *MTHFR*_677_C>T and *MTHFR*_1298_A>C genotypes with breast cancer risk may be attributed to variations of study size and design, particularly ethnicity and nonsporadic breast cancers.

Table 1. Genotype frequencies of polymorphic loci in genes encoding enzymes involved in folate metabolism in breast cancer cases and controls

Polymorphism	Genotype/allele	Cases, n (%)	Controls, n (%)	OR _{adj} (95% CI)
<i>MTHFR</i> _677_C>T	All*			
	CC	249 (43)	261 (41)	1.00 ^{†,‡}
	CT	274 (47)	279 (44)	1.04 (0.82-1.33)
	TT	61 (10)	93 (15)	0.69 (0.48-1.00)
	T	(32)	(37)	
	Premenopausal			
	CC	62 (44)	59 (40)	1.00 ^{§,‡}
	CT	66 (47)	68 (46)	0.86 (0.51-1.44)
	TT	13 (9)	20 (14)	0.60 (0.26-1.36)
	Postmenopausal			
	CC	187 (42)	202 (42)	1.00 ^{§,‡}
	CT	208 (47)	211 (43)	1.06 (0.80-1.41)
	TT	48 (11)	73 (15)	0.71 (0.47-1.09)
	<i>MTHFR</i> _1298_A>C	All*		
AA		273 (47)	295 (47)	1.00 ^{†,‡}
AC		256 (44)	266 (42)	1.04 (0.82-1.32)
CC		53 (9)	73 (12)	0.78 (0.53-1.16)
C		(31)	(32)	
Premenopausal				
AA		65 (46)	69 (47)	1.00 ^{§,‡}
AC		59 (42)	63 (43)	1.11 (0.66-1.87)
CC		16 (11)	15 (10)	1.22 (0.53-2.77)
Postmenopausal				
AA		208 (47)	226 (46)	1.00 ^{§,‡}
AC		197 (45)	203 (42)	1.04 (0.79-1.37)
CC		37 (8)	58 (12)	0.69 (0.43-1.08)
<i>TYMS</i> _1494_del TAAAGT		All*		
	ins/ins	272 (47)	292 (48)	1.00 ^{†,‡}
	ins/del	245 (43)	267 (44)	0.97 (0.76-1.24)
	del/del	58 (10)	51 (8)	1.22 (0.81-1.85)
	del	(31)	(33)	
	Premenopausal			
	ins/ins	55 (40)	62 (45)	1.00 ^{§,‡}
	ins/del	67 (49)	68 (49)	1.08 (0.64-1.84)
	del/del	15 (11)	9 (6)	1.82 (0.69-4.79)
	Postmenopausal			
	ins/ins	217 (50)	230 (49)	1.00 ^{§,‡}
	ins/del	178 (41)	199 (42)	0.94 (0.71-1.24)
	del/del	43 (10)	42 (9)	1.13 (0.70-1.81)
	<i>MTR</i> _2756_A>G	All*		
AA		366 (63)	415 (65)	1.00 ^{†,‡}
AG		197 (34)	193 (30)	1.17 (0.91-1.49)
GG		22 (4)	27 (4)	0.95 (0.53-1.71)
G		(21)	(19)	
Premenopausal				
AA		84 (59)	89 (60)	1.00 ^{§,‡}
AG		54 (38)	48 (32)	1.34 (0.80-2.24)
GG		4 (3)	11 (7)	0.30 (0.09-1.09)
Postmenopausal				
AA		282 (64)	362 (67)	1.00 ^{§,‡}
AG		143 (32)	145 (30)	1.14 (0.86-1.52)
GG		18 (4)	16 (3)	1.36 (0.67-2.73)

*Allele frequencies are in agreement with published data (13).

[†]OR conditional on age in 5-year group adjusted for menopausal status, smoking status, body mass index, breast cancer in mother or sister, parity, hormone replacement therapy, and oral contraceptives.

[‡]Reference.

[§]OR conditional on age in 5-year group adjusted for smoking status, body mass index, breast cancer in mother or sister, parity, hormone replacement therapy, and oral contraceptives.

Table 2. Haplotype frequencies of *MTHFR*_677_C>T and *MTHFR*_1298_A>C in breast cancer cases and controls

<i>MTHFR</i> _677	<i>MTHFR</i> _1298	Expected frequencies (%)	Cases (%)	Controls (%)	OR* (95% CI)
C	A	44	45	40	1.00 [†]
C	C	21	25	28	0.80 (0.66-0.98)
T	A	24	30	32	0.81 (0.67-0.98)
T	C	11	0	0	—

*Crude ORs.

†Reference.

In our study of Caucasian women of the GENICA case-control study, we did not identify a significant association of *MTHFR* polymorphisms with breast cancer risk. Comparison of our data with those from large case-control studies (>700 study participants) of women with related ethnicity showed that also White women from the Multiethnic Cohort (20) failed to reveal a breast cancer risk association with *MTHFR* genotypes. Yet, English-speaking women of the Long Island Study showed a significant excess risk with the *MTHFR*_677_TT genotype (OR, 1.37; 95% CI, 1.06-1.78; ref. 15). However, the latter is reported to be of mixed ethnicity, and it is noteworthy that Long Island has the highest breast cancer incidence in the United States, which has been suspected to be potentially linked to environmental pollution (32). It has been shown that polycyclic aromatic hydrocarbons were associated with an increased breast cancer risk, and we may infer that these and yet other unknown environmental confounders may have contributed to that risk association. This view is in line with observations from the Shanghai Breast Cancer study, in which a significant breast cancer risk was observed as an interactive effect between *MTHFR*_677 genotypes and low folate intake being highest for *MTHFR*_677_TT (OR, 2.51; 95% CI, 1.37-4.60; ref. 25) or in the Breast Cancer Study from Korea, in which this interactive effect was seen for low intake of green vegetables (21). Dietary deficiency in folate by itself is an appraised breast cancer risk factor, and it has been shown that environmental exposures, such as alcohol intake (33-36) and estrogen (22), cause folate deficiency, thus promoting the risk to develop breast cancer.

Lack of an association of *MTHFR* polymorphisms with breast cancer risk was also observed in African American, Latino, and Hawaiian women from the aforementioned Multiethnic Cohort (20) and in smaller studies from Scotland (24); Orange County, CA (23); Korea (21); Finland (17); and Greece (19). In contrast, risk associations with *MTHFR*_677_TT were identified in Jewish women with bilateral breast cancer or combined breast cancer and ovarian cancer (18) and in familial breast cancer cases with a family history of breast cancer or bilateral breast cancer from Wessex, England (14). Although these findings seem contradictory, direct comparisons should be prohibitive due to the strong hereditary and/or familial aspects addressed in these studies. This may also refer to a small study with hospital controls and non-age matching from Turkey that showed an increased breast cancer risk with both *MTHFR* polymorphisms (16).

We confirmed known *MTHFR* haplotype frequencies (37). No association with breast cancer risk was identified for *MTR*_2756_A>G and *TYMS*_1494_del (TAAAGT) polymorphisms either alone or in combination. This is the first time that genotyping data of these DNA methylation and DNA synthesis-regulating enzymes have been provided within a breast cancer association study.

Our study has an 80% power to detect a minimum OR of 1.3 for the four polymorphisms ($\alpha = 0.05$, two-sided test). Importantly, we identified a 2.8- and 3.5-fold increased breast cancer risk in the GENICA study population with respect to genotype and haplotype of the DNA repair enzyme ERCC2 (26). Our questionnaire data were insufficient with respect to

an estimation of folate intake; therefore, we could not test for this association. Yet, we consider our findings of a lack of *MTHFR* genotype-associated breast cancer risk confirmatory for Caucasian women and support the notion that the observed folate intake-dependent breast cancer risk in other studies may be insignificantly contributed by *MTHFR*, *MTR*, and *TYMS* genotypes.

Acknowledgments

We thank all women who participated in this study; the associated members of the GENICA Network Scientific Advisory Board: Hermann M. Bolt, M.D., Ph.D. (Institut für Arbeitsphysiologie an der Universität Dortmund); Michel Eichelbaum, M.D. (Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart); Hans Vetter, M.D. (Medizinische Universitäts-Poliklinik Bonn); the clinicians and hospitals: Walther Kuhn, M.D. (Universitätsklinikum Bonn); Uwe-Jochen Goehring, M.D. and Horst Wilms, M.D. (Johanniter-Krankenhaus Bonn); Heinrich Mause, M.D. (Gemeinschaftskrankenhaus St. Elisabeth-St. Petrus Bonn); Volker Pelzer, M.D. (Marien-Hospital Bonn); Michael Kaiser, M.D. (Malteser-Krankenhaus Bonn-Hardtberg); Rolf-Eberhard Herzog, M.D. (Evangelisches Waldkrankenhaus Bad-Godesberg); Sigrid Milz, M.D. and Wolfgang Nohl, M.D. (St. Johannes Krankenhaus Bad-Honnef); Karl-Heinz Schlensker, M.D. (Klinikum Rhein-Sieg); Robert Kampmann, M.D. (St. Josef-Hospital Troisdorf); Bernd Werling, M.D. (Krankenhaus Troisdorf-Sieglar); Norbert Golz, M.D. (Marien-Hospital Euskirchen); Matthias Winkler, M.D. and Peter-Karl Abramowski, M.D. (Kreiskrankenhaus Mechernich); the pathologists: Reinhard Büttner, M.D. and Hans-Peter Fischer, M.D. (Universitätsklinikum Bonn); Magdolna Bollmann, M.D., Reinhard Bollmann, M.D., Dietmar Kindermann, M.D., and Rainer Nikorowitsch, M.D. (Bonn); Jürgen Vogel, M.D., Mathias Feldmann, M.D., and Jürgen Gerlach, M.D. (Siegburg); the epidemiologists: Ulrich Ranft (Institut für Umweltmedizinische Forschung, Düsseldorf); Heinz-Erich Wichmann, M.D., Ph.D., Rolf Holle, Ph.D., and Hannelore Nagl (GSF-National Research Center for Environment and Health, Institute of Epidemiology, Neuerberg); the interviewers: Mette Besuden, Martin Black, Sandra Gschwendtner, Miriam Knie, Annette Kramer, Robert Priemke, Astrid Prömse, Miriam Rossa, Heiko Schneider, Johanna Scholl, Katja Tamme, Matthias Wenghöfer, Bernd Wiesenhütter, and Melanie Wollenschein; and the laboratory technical assistants: Sandra Brod and Silke Schöneborn.

References

- Choi SW, Mason JB. Folate status: effects on pathways of colorectal carcinogenesis. *J Nutr* 2002;132:2413-8.
- Kim YI. Folate and carcinogenesis: evidence, mechanisms, and implications. *J Nutr Biochem* 1999;10:66-88.
- Mason JB, Choi SW. Folate and carcinogenesis: developing a unifying hypothesis. *Adv Enzyme Regul* 2000;40:127-41.
- Ulrich CM, Kampman E, Bigler J, et al. Colorectal adenomas and the C677T *MTHFR* polymorphism: evidence for gene-environment interaction? *Cancer Epidemiol Biomarkers Prev* 1999;8:659-68.
- Ulrich CM, Bigler J, Velicer CM, et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. *Cancer Epidemiol Biomarkers Prev* 2000;9:1381-5.
- Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet* 1995;10:111-3.
- Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (*MTHFR*) associated with decreased enzyme activity. *Mol Genet Metab* 1998;64:169-72.
- Weisberg IS, Jacques PF, Selhub J, et al. The 1298A>C polymorphism in

- methylenetetrahydrofolate reductase (MTHFR): *in vitro* expression and association with homocysteine. *Atherosclerosis* 2001;156:409–15.
9. Mandola MV, Stoecklacher J, Zhang W, et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. *Pharmacogenetics* 2004;14:319–27.
 10. Harmon DL, Shields DC, Woodside JV, et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. *Genet Epidemiol* 1999;17:298–309.
 11. Leclerc D, Campeau E, Goyette P, et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cBlG complementation group of folate/cobalamin disorders. *Hum Mol Genet* 1996;5:1867–74.
 12. Matsuo K, Suzuki R, Hamajima N, et al. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. *Blood* 2001;97:3205–9.
 13. Sharp L, Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. *Am J Epidemiol* 2004;159:423–43.
 14. Campbell IG, Baxter SW, Eccles DM, Choong DY. Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer. *Breast Cancer Res* 2002;4:R14.
 15. Chen J, Gammon MD, Chan W, et al. One-carbon metabolism, MTHFR polymorphisms, and risk of breast cancer. *Cancer Res* 2005;65:1606–14.
 16. Ergul E, Sazci A, Utkan Z, Canturk NZ. Polymorphisms in the MTHFR gene are associated with breast cancer. *Tumour Biol* 2003;24:286–90.
 17. Forsti A, Angelini S, Festa F, et al. Single nucleotide polymorphisms in breast cancer. *Oncol Rep* 2004;11:917–22.
 18. Gershoni-Baruch R, Dagan E, Israeli D, et al. Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. *Eur J Cancer* 2000;36:2313–6.
 19. Kalemli TG, Lambropoulos AF, Gueorguiev M, et al. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. *Cancer Lett* 2005;222:57–65.
 20. Le Marchand L, Haiman CA, Wilkens LR, Kolonel LN, Henderson BE. MTHFR polymorphisms, diet, HRT, and breast cancer risk: the multiethnic cohort study. *Cancer Epidemiol Biomarkers Prev* 2004;13:2071–7.
 21. Lee SA, Kang D, Nishio H, et al. Methylenetetrahydrofolate reductase polymorphism, diet, and breast cancer in Korean women. *Exp Mol Med* 2004;36:116–21.
 22. Lin WY, Chou YC, Wu MH, et al. The MTHFR C677T polymorphism, estrogen exposure and breast cancer risk: a nested case-control study in Taiwan. *Anticancer Res* 2004;24:3863–8.
 23. Semenza JC, Delfino RJ, Ziogas A, Anton-Culver H. Breast cancer risk and methylenetetrahydrofolate reductase polymorphism. *Breast Cancer Res Treat* 2003;77:217–23.
 24. Sharp L, Little J, Schofield AC, et al. Folate and breast cancer: the role of polymorphisms in methylenetetrahydrofolate reductase (MTHFR). *Cancer Lett* 2002;181:65–71.
 25. Shrubsole MJ, Gao YT, Cai Q, et al. MTHFR polymorphisms, dietary folate intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. *Cancer Epidemiol Biomarkers Prev* 2004;13:190–6.
 26. Justenhoven C, Hamann U, Pesch B, et al. ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population. *Cancer Epidemiol Biomarkers Prev* 2004;13:2059–64.
 27. Pesch B, Ko Y, Brauch H, et al. Factors modifying the association between hormone-replacement therapy and breast cancer risk. *Eur J Epidemiol* 2005;20:699–711.
 28. Illig T, Bongardt F, Schopfer A, et al. Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. *J Clin Endocrinol Metab* 2004;89:5053–8.
 29. Changes and enhancement through release 8.0. Cary (NC): SAS Institute. SAS/STAT Software 2000.
 30. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. *Am J Hum Genet* 2001;68:978–89.
 31. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. *Am J Hum Genet* 2003;73:1162–9.
 32. Gammon MD, Santella RM, Neugut AI, et al. Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts. *Cancer Epidemiol Biomarkers Prev* 2002;11:677–85.
 33. Rohan TE, Jain MG, Howe GR, Miller AB. Dietary folate consumption and breast cancer risk. *J Natl Cancer Inst* 2000;92:266–9.
 34. Sellers TA, Kushi LH, Cerhan JR, et al. Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. *Epidemiology* 2001;12:420–8.
 35. Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. *JAMA* 1999;281:1632–7.
 36. Zhang SM, Willett WC, Selhub J, et al. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. *J Natl Cancer Inst* 2003;95:373–80.
 37. Gerhard DS, Nguyen LT, Zhang ZY, et al. A relationship between methylenetetrahydrofolate reductase variants and the development of invasive cervical cancer. *Gynecol Oncol* 2003;90:560–5.

One-Carbon Metabolism and Breast Cancer Risk: No Association of *MTHFR*, *MTR*, and *TYMS* Polymorphisms in the GENICA Study from Germany

Christina Justenhoven, Ute Hamann, Christiane B. Pierl, et al.

Cancer Epidemiol Biomarkers Prev 2005;14:3015-3018.

Updated version Access the most recent version of this article at:
<http://cebp.aacrjournals.org/content/14/12/3015>

Cited articles This article cites 36 articles, 9 of which you can access for free at:
<http://cebp.aacrjournals.org/content/14/12/3015.full#ref-list-1>

Citing articles This article has been cited by 9 HighWire-hosted articles. Access the articles at:
<http://cebp.aacrjournals.org/content/14/12/3015.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cebp.aacrjournals.org/content/14/12/3015>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.